Mittwoch, 8. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
PREVENT

Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery

Rekrutierend

NCT-Nummer:
NCT03216187

Studienbeginn:
Januar 2018

Letztes Update:
16.05.2023

Wirkstoff:
Pregabalin, Placebos

Indikation (Clinical Trials):
Pain, Postoperative

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Benno Rehberg-Klug

Collaborator:
University Hospital, Geneva, Centre Hospitalier Universitaire Vaudois, Insel Gruppe AG, University Hospital Bern,

Studienleiter

Benno Rehberg-Klug, MD
Study Director
HUG
Marc Suter, MD
Study Director
CHUV
Ulrike Stamer, MD
Study Director
Inselspital

Kontakt

Studienlocations
(3 von 6)

Alle anzeigen

Studien-Informationen

Detailed Description:

BACKGROUND Persistent postsurgical pain occurs in more than 30% of patients undergoing breast

cancer surgery. Evidence that gabapentinoids such as pregabalin may reduce the incidence of

persistent postsurgical pain is ambiguous, potentially because in previous trials

prophylactic treatment was administered to every patient undergoing surgery. The patients at

low risk of long term pain, were exposed to side effects without much benefit to expect.

AIM Validating or refuting the utility of pregabalin to prevent long term post-operative pain

in patients at high risk of persistent pain after breast cancer surgery.

METHODS Randomized, double-blind, placebo-controlled trial of pregabalin (2*150mg from the

day before breast cancer surgery until 2 weeks after surgery) in patients at high risk of

persistent pain (>30%). High-risk patients are identified by a risk score derived from a

previous observational study. The main outcome is the incidence of clinically important pain

(necessitating analgesic treatment, or having an intensity of >3 at rest or >5 on movement)

at 3 months after surgery. Secondary outcomes are: incidence of neuropathic pain, pain

interference, and incidences at 6 and 12 months of follow-up. In addition, side effects of

pregabalin and the retention rate during the treatment period will be monitored, as well as

patient expectancies.

RELEVANCE This is the first study for prevention of persistent postoperative pain which

targets only high-risk patients, thus lowering a false negative outcome and averting the risk

of side effects for patients at low risk.

The study is powered to show a reduction of the incidence of clinically important pain at 3

months of 20%. In the case the study shows that this can be achieved and pregabalin is well

tolerated, the preventive use of pregabalin for breast cancer surgery would be justified at

least in high-risk patients. On the other hand, a negative result would indicate the futility

of pregabalin prevention, which is already in routine use in many hospitals.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- patients scheduled for breast surgery for cancer, either breast-conserving

(tumorectomy/ quadrantectomy) or mastectomy, with or without immediate reconstruction,

and with or without axillary dissection.

- patients of 18 years or more scheduled for above mentioned type of surgery

- ability to speak and read French, English or German

- high (>30%) risk of clinically important persistent pain: identified with 2 or more

points of a risk score including the items: pre-existing pain at surgical site (2

points), history of depression (1 point), age < 50 years (1 point), and high expected

acute pain (>6/10, 1 point).

- Informed Consent as documented by signature.

Exclusion Criteria:

- Inability to understand the consent form and to follow the procedures of the study,

e.g. due to language problems, psychological disorders, dementia, etc. of the

participant

- Participation in another study with investigational drug within the 30 days preceding

and during the present study,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent

persons

- Pregnancy or lactation - Renal insufficiency (creatinine clearance < 60 ml/min)

- Allergy to pregabalin or the ingredients of the capsules

- Long-term preoperative therapy with gabapentinoids or high-dose opioids (more than 60

mg of morphine equivalents)

- Symptomatic cardiac insufficiency (peripheral oedema, NYHA class III - marked

limitation of physical activity)

- Suicidal ideation, identified by the question: "have you been bothered by thoughts

that you would be better off dead, or of killing yourself?"

- Planned fertility preservation immediately after surgery before a planned chemotherapy

- Known or suspected non-compliance, or substance-use disorder with impact on medication

adherence

Studien-Rationale

Primary outcome:

1. incidence of "clinically important pain" at 3 months after surgery (Time Frame - 3 months):
"Clinically important pain" is defined by: taking analgesics for pain at the surgical site OR average resting pain at the surgical site >3/10 OR average movement-induced pain at the surgical site >5/10.



Secondary outcome:

1. Pregabalin-related side effects (Time Frame - 10 days):
blurred vision or diplopia, somnolence or sleepiness, abnormal thinking, confusional state, disturbed attention, and falls, as well as the effects noted in the "generic assessment of side effects" GASE questionnaire

2. retention rates of pregabalin treatment (Time Frame - 30 days)

3. acute pain intensity and patient-reported pain outcome at 24h (Time Frame - 24 hours):
PAIN-OUT questionnaire

4. pain intensity at rest and movement, pain interference (Time Frame - 3, 6, and 12 months):
Brief Pain Inventory, BPI

5. neuropathic pain (Time Frame - 3, 6, and 12 months):
incidence of neuropathic pain defined as a DN4-self-evaluation score ≥4

6. patient-reported relevance of pain (Time Frame - 3, 6, and 12 months):
response to the question: "do you consider your pain as significant?"

7. Patient-reported acceptance of the preventive treatment (Time Frame - 3 months):
response to the question "In retrospect, do you consider the preventive treatment worthwhile, given your pain outcome and your experience of taking the medication?")

8. Expectations about treatment benefits before treatment and after (Time Frame - 10 days):
responses to the questions: "How much pain do you expect 3 months from now?"" "How efficient do you think the study treatment is against the long-term pain (i.e. what is the success rate in %)?" "How well do you think it will work for you? (i.e. reduction in pain score 0-10)". Beliefs about treatment attribution after 10 days of treatment (question: "Do you think that you received the real drug or the placebo?")

Studien-Arme

  • Experimental: Pregabalin
    Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
  • Placebo Comparator: Placebo
    Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.

Geprüfte Regime

  • Pregabalin (Pregabalin 150mg capsules):
    pregabalin 150 mg capsules
  • Placebos (placebo capsules):
    capsules identical to pregabalin but without active drug

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.